Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor

We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumou...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Donald, Tan, Min Han, Khor, Damian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717/
https://www.ncbi.nlm.nih.gov/pubmed/34511423
http://dx.doi.org/10.1136/bcr-2021-244271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717/
https://www.ncbi.nlm.nih.gov/pubmed/34511423
http://dx.doi.org/10.1136/bcr-2021-244271

Ejemplares similares